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Objective: To determine the potential of periosteal cells to inﬁltrate poly-3-caprolactone (PCL) nanoﬁber
scaffolds in vivo and subsequently produce cartilage in vitro.
Design: PCL nanoﬁber scaffolds, with or without chitosan-coating were implanted under periosteum in
6-month-old rabbits. Transforming growth factor-b1 (TGF-b1) or vehicle was injected into each implant
site. After 1, 3, 5 or 7 days, scaffolds were removed, separated from the periosteum, and the scaffolds
and periosteum were cultured separately for 6 weeks under chondrogenic conditions. Sulfated
glycosaminoglycan (GAG), type II collagen, DNA content, cartilage yield, and calcium deposition were
then analyzed.
Results: Cell inﬁltration was observed in all scaffolds. Cartilage formation in the uncoated scaffolds
increased with duration of implantation (maximum at 7 days). Cells in the uncoated scaffolds implanted
for 7 days produced signiﬁcantly higher levels of both GAG [560 (95% conﬁdence interval (CI), 107e1013)
vs 228 (95% CI, 177e278) mg GAG/mg DNA] and cartilage yield [9% (95% CI, 3e14%) vs 0.02% (95% CI,
0e0.22%)] compared to chitosan-coated scaffolds (P¼ 0.006 or less). There was no signiﬁcant difference
in GAG content or cartilage yield between the TGF-b1-injected and vehicle-injected scaffolds. However,
signiﬁcantly more mineral deposition was detected in TGF-b1-injected scaffolds compared to vehicle-
injected scaffolds (P< 0.0001). Cartilage yield from the periosteum, moreover, was signiﬁcantly
increased by subperiosteal TGF-b1 injections (P< 0.001). However, this response was reduced when
chitosan-coated scaffolds were implanted.
Conclusions: This study demonstrates that it is possible to seed PCL nanoﬁber scaffolds with periosteal
cells in vivo and subsequently produce engineered cartilage in vitro.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Tissue engineering represents a viable option to repair cartilage
and restore joint function1,2. This approach requires a cell source,
matrix or scaffold, and appropriate growth factors to promote
chondrogenesis3. Current cell-based cartilage repair approaches
such as autologous chondrocyte transplantation require in vitro
culture to expand cells, and seed them onto a scaffold if
applicable4e6. We are interested in developing autologous cell-
based cartilage repair approaches that do not require harvest of
healthy cartilage or in vitro culture.
Periosteal grafts meet these criteria and can be used clinically to
resurface joints7. Periosteum contains chondrogenic and osteogenicregory G. Reinholz, Cartilage
nic College of Medicine, 200
-5237; Fax: 1-507-284-5075.
Reinholz).
s Research Society International. Pcells in the form of mesenchymal stem cells (MSCs)7e18. In addition
to using periosteum as a graft, a space can be created between the
cambium layer and underlying bone to serve as an in vivo biore-
actor, in which a graft, or scaffold can be implanted. For example,
Cohen and LaCroix19 implanted free periosteal grafts under the
adjacent periosteum of rabbits and demonstrated cartilage forma-
tion within the grafts. Recent studies have also demonstrated that
periosteal cells can inﬁltrate hyaluronic acid gels or porous PCL
scaffolds when implanted subperiosteally and form cartilage or
bone in situ13,14,20.
We hypothesize that a scaffold in the form of a folded or rolled
thin sheet could be implanted under the periosteum to capture
chondrogenic cells. Subsequently, the cell-seeded scaffold could be
separated from the periosteum, unfolded and used to resurface
a large chondral defect or perhaps an entire joint surface. The ﬁrst
step in this process is to determine if a synthetic scaffold with
suitable properties could capture periosteal cells in vivo and if these
captured cells would form cartilage upon removal from the
implantation site.ublished by Elsevier Ltd. All rights reserved.
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scaffolds for cartilage tissue engineering21e30. Nanoﬁbers mimic
the natural extracellular matrix (ECM) and are suitable candidates
for cartilage tissue engineering22,31. PCL nanoﬁber sheets are also
ﬂexible and can be rolled or folded and contoured to cover the
surface of a joint. Therefore, PCL nanoﬁber scaffolds are excellent
candidates for this study.
Chitosan, a biopolymer found in the shells of crustaceans, is
known for its biocompatibility, antibacterial properties, degrad-
ability, wound-healing capability, and support of chondrocyte dif-
ferentiation32e34. Therefore, we hypothesized that coating PCL
nanoﬁber scaffolds with chitosanwould enhance the chondrogenic
potential of periosteal cells.
This study was designed to determine the potential of periosteal
cells to inﬁltrate uncoated and chitosan-coated PCL nanoﬁber
scaffolds in vivo after subperiosteal implantation and form cartilage
in vitro within the scaffolds after removal. We also, examined the
effect of injecting TGF-b1 in the implantation site on the chon-
drogenic potential of the periosteal cells in the scaffolds and the
implant-site periosteum. The in vitro culture step used in this
experiment was employed as a method to determine proof-of-
concept. From a clinical standpoint, we envision that a culture step
would not be necessary for cartilage repair. Rather, after implanting
the scaffold under the periosteum for a suitable duration, the
resulting cell-seeded scaffold would be harvested and used directly
to repair the defective cartilage during the same surgical procedure,
in the same manner as periosteal transplantation.
Materials and methods
Nanoﬁbrous scaffold synthesis
A 9.5 wt% homogeneous solution of PCL was prepared by dis-
solving 1.05 g of 80,000 Mn PCL (SigmaeAldrich, St. Louis, MO, cat.
#440744, batch #12331AB) in 0.8 g N,N-dimethylformamide
(Fisher Scientiﬁc), 6.0 g chloroform (Fisher Scientiﬁc), and 3.2 g
acetone (Fischer Scientiﬁc). The solution was stirred gently for 4 h
and transferred to a 30 ml glass syringe ﬁtted with a 10 cm, 20-
gauge needle. A 30 kV electric ﬁeld was applied to the solution as it
was dispensed at 3.3 ml/h. The nanoﬁbers were collected on a glass
plate at a distance of 15 cm from the tip of the needle. Approxi-
mately four batches were needed to make a 1 mm thick scaffold.
The average diameter of ﬁbers was approximately 400 nm based on
light microscope observation.
Nanoﬁber implant preparation
Two hundred and ﬁfty-six cylindrical samples were cut from the
1 mm thick nanoﬁber sheet using a 3.5 mm dermal punch (Miltex
Inc., York, PA) and divided into two groups. Chitosan was used to
coat 128 samples, while the other 128 samples were left uncoated.
Control samples were soaked in 50 wt% acetic acid solution, while
the coated samples were soaked in 50 wt% acetic acid solutionwith
0.5 wt% of 85% deacetylated chitosan (Sigma, St. Louis, MO) for 12 h.
Both groups were freeze-dried and gas sterilized using ethylene
oxide.
Scaffold cell seeding/implantation
All procedures were conducted with the approval of our Insti-
tutional Animal Care and Use Committee. Thirty-two skeletally
mature 6-month-old New Zealand white rabbits (4.2e5.2 kg) were
used in this study. Under general anesthesia induced by an intra-
muscular injection of ketamine/xylazine/acepromazine (50 mg/
5 mg/0.75 mg/kg of body weight, respectively), both hind limbswere shaved and prepared with Techni-care surgical scrub (Care-
Tech Laboratories, St. Louis, MO). A 1 cm skin incision was made
over the medial proximal tibia. The underlying deep fascia was
retracted and a 4 mm incision was made in the underlying peri-
osteum. Inserting a sharp 2.5 mm periosteal elevator into the
incision, the periosteum was elevated off the bone creating
a 1 cm 1 cm subperiosteal space. Individual rabbits received
either uncoated scaffolds or chitosan-coated scaffolds not both.
Four uncoated or chitosan-coated PCL nanoﬁber scaffolds were
implanted into each subperiosteal space [Fig. 1(A,B)]. After closure
of the subperiosteal spacewith 4-0 silk suture, TGF-b1 (200 ng) was
injected in one limb while vehicle was injected in the contralateral
limb using a 30 gauge, ½ inch needle (Precision Glide Needle,
Franklin Lakes, NJ) into the subperiosteal space under each of the
four scaffolds. The fascia and skin were closed with 3-0 Vicryl
subcuticular sutures. After 1, 3, 5 or 7 days, the rabbits were
euthanized using sodium pentobarbital (100 mg/kg body weight)
and the scaffolds were removed by separating them from the
periosteum [Fig. 1(C,D)]. The overlying periosteum was harvested
and cut into four explants corresponding to the regions previously
occupied by the scaffolds.
In vitro culture of seeded scaffolds and periosteum
The periosteal cell-seeded scaffolds and corresponding peri-
osteal explants were obtained within 15 min of death and placed
in Dulbecco’s Modiﬁed Eagle Media (DMEM), 10% fetal bovine
serum (FBS) with penicillin/streptomycin and 1 mM proline at
4C. Within 90 min, the scaffolds and explants were transferred
to chondrogenic culture as previously described12. Brieﬂy, 24-
well culture plates were coated with 1% agarose (Bio-Rad,
Hercules, CA) followed by 0.25 ml of 1% low-melt agarose (Bio-
Rad, Hercules, CA) in DMEM. After gelling the agarose on ice,
periosteal explants or scaffolds were placed on the agarose bed
(one sample/well). Another 0.75 ml of 1% low-melt agarose in
DMEM was then added and agarose was gelled on ice. One
milliliter of liquid medium was then added to each well. The
medium was supplemented with 10 ng/ml TGF-b1 for the ﬁrst 2
days of culture and 50 mg/ml L-ascorbic acid throughout the
culture period. The liquid medium was replaced three times each
week. The cultures were maintained at 37C, 5% CO2 and 95% air.
After 6 weeks, the scaffolds were removed from culture and cut
in half. One half was analyzed for cartilage content, mineral
deposition and immunohistochemistry for type II collagen. The
other scaffold halves were analyzed for GAG and dsDNA content
(two samples from each limb), or collagen typing analysis35 (two
samples from each limb).
Cartilage content and mineral deposition
The half scaffolds and periosteal explants were weighed, ﬁxed in
4% paraformaldehyde in phosphate buffered saline (PBS) for
45 min, washed through a series of graded ethanol (50, 70, 95 and
100%), followed by washing in a 50:50 mixture of 100% ethanol and
Histoclear, 100% Histoclear, a 50:50 mixture of Histoclear and Par-
aplast X-tra, and embedded in 100% Paraplast X-tra. For the scaffold
samples, the edge where the scaffold had been cut in half was the
section exposed for analysis. The periosteal explants were
randomly shaped after the culture period and were not embedded
in any particular orientation. The samples were cut into 3 mm thick
sections, and stained with safranin O/fast green. Computerized
histomorphometry was applied by a blinded technician to deter-
mine percentage cartilage yield (% area stained red vs total tissue
area) in each sample using Vidas Image Analysis Program (Zeiss,
software version 2.1)36. Positive staining occurred when hue and
Fig. 1. Implantation (A & B) and harvesting (C & D) of PCL nanoﬁber scaffolds. (A) Subperiosteal implantation. (B) Closure with scaffolds under periosteum. (C) Exposure of scaffolds
after 7 days of implantation. (D) Harvesting of scaffold from periosteum for in vitro culture. The black arrows indicate the location of PCL nanoﬁber scaffolds. The white arrow shows
the periosteum after removal of PCL nanoﬁber scaffold.
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the area over which this occurred was recorded. The parafﬁn
embedded samples from the 7-day implantation group were also
stained using the von Kossa technique and mineral deposition was
evaluated using a simple histological method (based on a previ-
ously validated histological scoring technique37). The specimens
were assigned a score from 0 to 3 by a blinded technician where
0¼ no black von Kossa staining; 1¼ von Kossa staining in less than
half the specimen; 2¼ von Kossa staining in more than half the
specimen; and 3¼ von Kossa staining throughout or nearly
throughout the specimen.
GAG and DNA content analysis
The other half of the scaffolds was rinsed in 1 PBS, digested in
1 ml of 50 mg/ml proteinase K (Roche, IN, USA) dissolved in
100 mMK2HPO4 (pH 8.0) for 16 h at 60C in a water bath and
digestion was inactivated in a 90C water bath for 10 min. Using
100 ml of this working solution, GAG content was quantiﬁed
following instructions provided by the manufacturer in the
Dimethyl-Methylene Blue Assay Kit (DMMB, Blyscan Sulfated
Glycosaminoglycan Assay Kit; Biocolor Ltd., NI, UK). Bound dye
values were quantiﬁed at 656 nm using a SpectraMax Plus spectro-
photometer (Molecular Devices, CA, USA). Yield was normalized to
dsDNA content. dsDNA content was determined using Quant-iT
PicoGreen dsDNA Kit (Invitrogen Eugene, OR) with a Fluorostar
Plate Reader (BMG Labtechnologies, Offenburg, Germany) and
100 ml working solution from digest described above. The back-
ground values obtained from unseeded PCL and chitosan-coatedPCL were subtracted from the dsDNA values to get the ﬁnal dsDNA
content of the engineered tissue.
Collagen typing
Quantitative collagen typing was performed using a published
technique for measuring the relative amount of type II collagen
with respect to type I collagen in tissue samples38. This technique
has been modiﬁed to permit the analysis of very small samples
(1e10 mg) without initial puriﬁcation of the collagen35. Samples
were weighed, and collagen peptides were cleaved with 0.5 ml 5%
cyanogen bromide (CNBr) in deaerated 88% formic acid. In prepa-
ration for electrophoresis, samples were dissolved in 0.063 M
TriseHCl, pH 8, 3.3% SDS, 10% glycerol, 5% 2-mercaptoethanol,
0.001% bromophenol blue, at a concentration of 8 mg (wet weight)
of sample per micro liter of sample buffer. A 1 ml volume of sample
was loaded onto 20% gels, and sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis was performed using a Phast
System (Pharmacia LKB, Uppsala, Sweden). A standard derived
from articular cartilage was run in each gel to ensure that the
banding pattern for 100% type II collagen was accurately repre-
sented. The gels were stained with Coomassie blue and scanned on
a laser densitometer. Typically, the percentage of type II collagen
with respect to type I collagen would be determined by measuring
the ratio of the a1(II)CB10 to the a1(I)CB7, 8 and a1(II)CB11 peaks in
each lane. Unfortunately, the only detectable bands on the gels
were those from the articular cartilage controls. Therefore, the
collagen typing analysis was inconclusive due to interference by
PCL in the samples and the data are not presented.
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Immunohistochemistry for type II collagen was also per-
formed on select samples. The formalin ﬁxed parafﬁn
embedded samples were sectioned at 5 mm, deparafﬁnized and
treated with 3% H2O2 to inactivate endogenous peroxidase,
followed by incubation with protein block (Dako X0909, DAKO
North America, Inc., Carpinteria, CA). Mouse monoclonal anti-
collagen type II antibody, II-II6B3 (Developmental Studies
Hybridoma Bank, The University of Iowa, Department of
Biology, Iowa City), was applied using a 1/400 dilution from
432 mg/ml immunoglobulin (Ig) stock (concentration provided
by supplier) overnight at room temperature. Visualization was
performed using Mach3 Mouse HRP Polymer Detection (Ref.
#M3M530, Biocare Medical, Concord, CA) followed by incuba-
tion with diaminobenzidine. Sections were counterstained with
hematoxylin. Rabbit osteochondral tissue was used for positive
controls. Negative controls were prepared in the absence of
primary antibody.Fig. 2. Safranin O/fast green stained histological specimens of uncoated (AeF) and chitosan
weeks of culture. The specimens are the worst, a representative of the average, and the best b
the 7-day implantation group. For the samples with chitosan, the “Worst” is from the 7-day
The “Average” is from the 7-day TGF-b1 implantation group and has little to no cartilage st
cartilage on the periphery, and pink throughout the center.Statistical analysis
Data are expressed as means with a 95% conﬁdence interval (CI)
(lower limit, upper limit). Statistical differences between each
treatment group and corresponding vehicle control were evaluated
using one-way analysis of variance (ANOVA). Statistical differences
between treatment groups were evaluated using the least squares
means differences Student’s t test.
Results
Periosteal cell inﬁltration into PCL nanoﬁber scaffolds
During sample harvest, the uncoated scaffolds were more
tightly integrated with the periosteum compared to chitosan-
coated scaffolds. The uncoated scaffolds implanted for 5 and 7
days were particularly well attached to the surrounding perios-
teum leaving visible imprints in the periosteum upon removal
[Fig. 1(D)]. After the 6-week culture period, light microscopy-coated (GeL) PCL nanoﬁber scaffolds after 7 days of subperiosteal implantation and 6
ased on percent cartilage in the tissue sections. The samples without chitosan are from
no TGF-b1 implantation group, which is lacking in ECM and has no cartilage staining.
aining. The “Best” comes from the day 3 no TGF-b1 implantation group, stains red for
Table I
DNA content in periosteal cell-laden PCL nanoﬁber scaffolds
Duration of implant (days) Uncoated Chitosan-coated
Vehicle TGF-b1 Vehicle TGF-b1
DNA content (mg)
1 0.439 (0.4388e0.439) 0.439 (0.439e0.4394) 0.425 (0.413e0.436) 0.418 (0.406e0.429)
3 0.483 (0.446e0.520) 0.456 (0.421e0.490) 0.638* (0.443e0.832) 0.582**(0.387e0.776)
5 0.519 (0.484e0.554) 0.464 (0.429e0.500) 0.470 (0.363e0.576) 0.512 (0.412e0.611)
7 0.525 (0.473e0.577) 0.511 (0.455e0.566) 0.399 (0.390e0.408) 0.397 (0.389e0.404)
The data are presented as means with 95% CIs. The groupmarked (*) has signiﬁcantly higher DNA content than all other groups in the table except the group marked with (**).
The highest P-value occurred between this group and the uncoated, day 7, vehicle-injected group at P¼ 0.029. All other P-values when compared to this marked (*) value are
below this P-value. The group marked (**) had signiﬁcantly higher values of DNA content than all groups in the table with the exception of vehicle and TGF-b1-injected, day 7
uncoated scaffolds and vehicle-injected day 5 and day 3 uncoated scaffolds. The highest P-value amongst the groups signiﬁcantly different from (**) occurred between this
group and TGF-b1-injected, day 5 uncoated scaffolds with P¼ 0.0228. All other P-values when compared to this marked (**) value are below this P-value. These P-values are
based on the results of post-hoc testing using Student’s t test (n¼ 7 or 8).
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cell penetration into the scaffolds and attachment to PCL ﬁbers
with or without chitosan-coating or TGF-b1 injection. The DNA
content (Table I) in the uncoated scaffolds increased with dura-
tion of implantation reaching maximum in scaffolds implanted
for 7 days [vehicle: 0.525 (0.473e0.577) mg, n¼ 8; TGF-b1: 0.511
(0.455e0.566) mg, n¼ 7]. DNA content in chitosan-coated
scaffolds reached maximum after 3 days [vehicle: 0.638
(0.443e0.832) mg, n¼ 7; TGF-b1: 0.582 (0.387e0.776) mg, n¼ 7].
TGF-b1 injection did not signiﬁcantly alter DNA content in any of
the groups.
GAG synthesis
Normalized GAG content (mg GAG/mg DNA) [Fig. 3(A)] in
uncoated scaffolds increased with duration of implantation
reaching maximum in scaffolds implanted for 7 days [vehicle: 560
(107e1013), n¼ 8; TGF-b1: 728 (244e1213), n¼ 7], which was
signiﬁcantly higher than uncoated scaffolds implanted for 1 day
[vehicle: 11 (1e21), n¼ 7, P< 0.0001; TGF-b1: 2.2 (0e12), n¼ 7,
P¼ 0.0001], 3 days [vehicle: 57 (20e94), n¼ 7, P< 0.0001; TGF-b1:
19 (0e54), n¼ 8, P< 0.0001], or 5 days [vehicle: 160 (56e265),
n¼ 8, P¼ 0.0004; TGF-b1: 186 (80e291), n¼ 8, P< 0.0001]. There
was also signiﬁcantly more GAG produced in the uncoated scaffolds
implanted for 7 days compared to all chitosan-coated scaffold
groups including those implanted for 7 days [vehicle: 217
(166e268), n¼ 8, P¼ 0.0024; TGF-b1: 228 (177e278), n¼ 7,Fig. 3. GAG content and cartilage yield in periosteal cell-laden PCL nanoﬁber scaffolds. Uncoa
of rabbits for 1, 3, 5, or 7 days followed by 6 weeks of culture. The implant sites were injected
after 6 weeks of culture (n¼ 7 or 8). (B) Cartilage yield in periosteal cell-laden scaffolds afte
indicate values that are signiﬁcantly different than all other time points based on post-hocP< 0.0001]. These ﬁndings are reﬂected in the histology (Fig. 2) and
cartilage content results presented below [Fig. 3(B)]. The mean
normalized GAG content in chitosan-coated scaffolds implanted for
1 and 3 days was higher than uncoated scaffolds, but no signiﬁcant
difference was found. There were no signiﬁcant differences
between TGF-b1-injected scaffolds and vehicle controls across all
durations of implantation.
Cartilage content
Cartilage content was determined in the scaffolds and perios-
teal explants after the 6-week culture period based on safranin O/
fast green staining as described in the methods. Similar to the
GAG content results, percent cartilage produced in the scaffolds
was dependent on duration of implantation and whether the
scaffold was coated with chitosan or not [Fig. 3(B)]. In the scaf-
folds, cartilage content was negligible (<1.2%) except for uncoated
scaffolds implanted for 7 days [vehicle: 6.1% (0.5e11.8%), n¼ 16;
TGF-b1: 8.8% (3.2e14.4%), n¼ 16], which produced signiﬁcantly
more cartilage than all other groups (P< 0.0001). Also, this group
produced signiﬁcantly more cartilage than chitosan-coated scaf-
folds for all durations of implantation (P¼ 0.006 or less). However,
cartilage content in uncoated PCL scaffolds implanted for 7 days
was highly variable with a minimum¼ 0 and maximum¼ 45%.
This was not a rabbit-speciﬁc effect because there was no corre-
lation between the rabbit used and amount of cartilage produced
in the scaffolds. The TGF-b1-injected scaffolds were notted and chitosan-coated PCL nanoﬁber scaffolds were implanted under the periosteum
with either 200 ng TGF-b1 or vehicle. (A) GAG content in periosteal cell-laden scaffolds
r 6 weeks of culture (n¼ 16). The data presented are means with 95% CI. The asterisks
testing (P< 0.0001).
Fig. 4. Cartilage yield and wet weights of implant-site periosteum. Uncoated and chitosan-coated PCL nanoﬁber scaffolds were implanted under the periosteum of rabbits for 1, 3, 5,
or 7 days followed by 6 weeks of culture. The implant sites were injected with either 200 ng TGF-b1 or vehicle. (A) Cartilage yield and (B) wet weights of implant-site periosteum
after 6 weeks of culture. The data presented are means with 95% CI (n¼ 16). The brackets indicate values in the TGF-b1-injected groups that are signiﬁcantly different than the
corresponding vehicle controls based on post-hoc testing.
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cartilage content for all durations of implantation regardless of
being uncoated or chitosan-coated. Overall, the cartilage yield
results are consistent with the GAG content results describedFig. 5. Typical type II collagen immunohistochemical staining of uncoated (A & D) and chitos
7 days followed by 6 weeks of culture. (C & F) Representative implant-site periosteal explant
uncoated scaffold (A & D), the chitosan-coated scaffold (B & E) and the periosteal explant (C
Fig. 8 (A & B), respectively.previously [Fig. 3(A)]. Also, similar to the GAG content results and
safranin O/fast green staining, immunohistochemistry revealed
darker staining for collagen type II in uncoated scaffolds
compared to chitosan-coated scaffolds (Fig. 5).an-coated (B & E) PCL nanoﬁber scaffolds implanted under the periosteum of rabbits for
after 7 days of scaffold implantation followed by 6 weeks of culture. For reference, the
& F), are from serial sections of the samples shown in Fig. 2 (B & E), Fig. 2 (H & K), and
Fig. 6. Mineral deposition (based on von Kossa stained histological sections) in
uncoated (No Chitosan) and chitosan-coated (With Chitosan) PCL nanoﬁber scaffolds
and periosteum from the implant sites after 7 days of implantation and 6 weeks of
culture. The specimens were scored from 0 to 3 (based on a previously validated
histological scoring method37) by a blinded technician where 0¼ no staining;
1¼ partial staining <50%; 2¼ partial staining >50%; and 3¼ nearly complete or
complete staining of the section. The data presented are means with 95% CI (n¼ 16).
The asterisks indicate values that are signiﬁcantly different than the corresponding
vehicle control based on post-hoc testing (P< 0.0001).
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cultured separately from the scaffolds for 6 weeks and cartilage yield
was determined. Signiﬁcantly more cartilage was produced in the
periosteumwhen the implant sitewas injectedwith TGF-b1 comparedFig. 7. Von Kossa and safranin O/fast green stained histological sections of periosteal cell-lad
chitosan-coated (E & G) PCL nanoﬁber scaffolds and safranin O/fast green stained serial se
implant group with TGF-b1 injection (A, B, E & F) and vehicle injection (C, D, G & H) at theto vehicle regardless of duration of implantation (uncoated scaffolds
P< 0.0001; chitosan-coated P¼ 0.0014) (Figs. 4A and 8). Periosteum
harvested from above uncoated, TGF-b1-injected implantation sites
produced signiﬁcantly more cartilage than periosteum from above
chitosan-coated implantation sites (P¼ 0.0028). Interestingly, the wet
weights of the periosteum from above uncoated, TGF-b1-injected
implantation sites were also signiﬁcantly higher (P< 0.0001) than
periosteum from above chitosan-coated implantation sites [Fig. 4(B)].
Unlike the scaffolds, no obvious differences in immunohistochemistry
staining for type II collagen in the periosteal explants were observed
between the treatment groups (Fig. 5). The uncoated, TGF-b1-injected
groups produced mean amounts of cartilage comparable to or greater
thanhistoricaldataofperiosteumfromrabbits2and6-month-oldafter
culture [Fig. 4(A)]39. Notably, these groups produced a cartilage yield
statistically the same as results from our previous study in which we
injected TGF-b1 subperiosteally and waited 1, 3, 5, and 7 days before
harvesting the tissue and culturing under the same conditions40. This
study indicates that local TGF-b1 injections can rejuvenate periosteum
to the same extent despite the presence of scaffolds and loss of cells
when the scaffolds were removed.Mineral deposition
Histological specimens from the 7-day implantation groups
were stained using von Kossa technique to detect mineral deposi-
tion (Figs. 6e8). There was no signiﬁcant difference in mineral
deposition between uncoated and chitosan-coated scaffolds.
However, signiﬁcantly more mineral deposition was observed in
scaffolds receiving TGF-b1 injection vs vehicle controls (P< 0.0001)
in both uncoated [vehicle: 0.75 (0.35e1.15), n¼ 16; TGF-b1: 1.3en PCL nanoﬁber scaffolds. These sections show mineralization of uncoated (A & C) and
ctions (B, D, F & H) of the periosteal cell-laden scaffolds from the 7-day subperiosteal
implant site after 6 weeks of culture.
Fig. 8. Von Kossa and safranin O/fast green stained histological sections. These sections show mineralization of periosteal explants from the implantation sites of uncoated (A & C)
and chitosan-coated (E & G) PCL nanoﬁber scaffolds and safranin O/fast green stained serial sections (B, D, F & H) of periosteal explants from the 7-day subperiosteal implant group
with TGF-b1 injection (A, B, E & F) and vehicle injection (C, D, G & H) at the implant site after 6 weeks of culture. The asterisks indicate values that are signiﬁcantly different than the
corresponding vehicle control based on post-hoc testing (P< 0.0001).
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(0.04e0.83), n¼ 16; TGF-b1: 1.5 (1.11e1.89), n¼ 16] (Figs. 6 and 7).
Mineral deposition was minimal in the implant-site periosteum
and no signiﬁcant differences were observed between implant
types or between injections of vehicle vs TGF-b1 (Figs. 6 and 8).
Discussion
This study demonstrates that chondrogenic cells can inﬁltrate
PCL nanoﬁber scaffolds in vivo after subperiosteal implantation
and produce cartilage in vitro after removal from the periosteum.
This ﬁnding supports the notion that the subperiosteal space can
be used as an “in vivo bioreactor” for musculoskeletal tissue
engineering13,14,20. Another interesting ﬁnding is that periosteum
from the implant sites retained the ability to form cartilage in
vitro in response to in vivo injection of TGF-b1. These results
mimic our previous ﬁnding that subperiosteal injection of TGF-b1
signiﬁcantly increases in vitro periosteal cartilage yield in 6, 12
and 24-month rabbits40. However, as Simon et al. previously
demonstrated, this result may be due in part to stimulation of
cambium cells by elevation of the periosteum41. In any case, it
may be possible to use both the periosteal cell-laden PCL nano-
ﬁber scaffold and the implant-site periosteum for chondral or
osteochondral tissue regeneration. Speciﬁcally, since TGF-b1injection increased mineralization in the cell-seeded scaffold but
not in the surrounding periosteum, the cell-seeded scaffold in this
case might be used as a bone layer of an osteochondral defect
while using the periosteum as the cartilage layer. Of course this is
speculation based on the results from in vitro culture and would
need to be examined in vivo.
Cartilage formation in PCL nanoﬁber scaffolds was dependent on
duration of the implantation period. However, because the scaffolds
were only analyzed after the 6-week culture period, the initial cell
density of the scaffolds when placed into culture is unknown. This
makes it unclear if optimal cell density in the scaffolds or initiation of
cellular differentiation in vivo prior to removal of the scaffolds from
the periosteum is responsible for the increase in cartilage formation
over time. Nevertheless, after the 6-week culture period, cell inﬁl-
trationwas observed in all scaffolds regardless of injectionwith TGF-
b1 or vehicle, duration of implantation, and whether the scaffolds
were chitosan-coated or not. Based on GAG and cartilage content
analyses, signiﬁcant amounts of cartilage formed in the uncoated, 7-
day implantation group with no signiﬁcant difference observed
between TGF-b1 and vehicle-injected scaffolds. The amount of
cartilage produced by this experimental group is comparable to
historical data of in vitro cartilage yield produced from periosteum
harvested from 6-month rabbits39. However, based on the present
study,we hypothesize that longer implantationperiodswould result
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cell-seeded PCL nanoﬁber scaffolds.
Interestingly, the chitosan-coated scaffolds did not yield signif-
icant amounts of cartilage even though cell inﬁltration was
observed. In general, there was signiﬁcant homology in cellular
morphology and matrix within the chitosan-coated scaffolds. This
was noticeably different from uncoated groups as seen in Fig. 2.
While it is possible that the chitosan-coating may have slowed
cellular inﬁltration into the PCL nanoﬁber scaffolds resulting in
decreased in vitro chondrogenesis, it is also possible that the chi-
tosan-coating inhibited cell proliferation and/or chondrogenic
differentiation. The latter possibility is supported by the observa-
tion that periosteum from chitosan-coated scaffold implant sites
had signiﬁcantly lower wet weights and formed signiﬁcantly less
cartilage than periosteum from uncoated scaffold implant sites. A
potential biocompatibility issue with the chitosan-coating cannot
be ruled out from this experiment. The observed decrease in peri-
osteal explant wet weights in the chitosan-coated groups support
this notion, however, the DNA content of the scaffolds do not. The
observed lack of chondrogenesis in the chitosan-coated scaffolds is
in contrast to our previous results, which demonstrated chitosan-
coating of macro porous PCL scaffolds resulted in higher GAG
production from seeded human chondrocytes (unpublished
results) as well as published reports demonstrating chitosan
supports chondrocyte differentiation32e34. However, these appar-
ently conﬂicting results may be accounted for by the obvious
differences in approach between this study and other studies such
as cell type, scaffold design (pore size, ﬁber size, architecture etc.),
cell-seeding technique and culture conditions.
Because no signiﬁcant cartilage was observed in chitosan-
coated scaffolds, we speculated that the chitosan-coating might be
inducing the periosteal cells to differentiate into osteoblasts rather
than chondrocytes. Interestingly, while no difference in mineral
deposition was observed between uncoated and chitosan-coated
samples, a signiﬁcant increase in mineral deposition was observed
in the scaffolds when the implant site was injected with TGF-b1
compared to vehicle (Figs. 6 and 7). This observation raises an
obvious concern for the use of TGF-b1 injections in combination
with the periosteal cell-seeded PCL nanoﬁber scaffolds for cartilage
tissue engineering. However, if the periosteal cell-seeded scaffolds
were surgically implanted into a cartilage defect immediately after
removal from the periosteum or if the scaffolds were exposed to
continuous TGF-b1 in the culture medium (as opposed to only the
ﬁrst 2 days) such mineral deposition might be inhibited42e44.
Additional studies are needed to test these approaches.
The approach described herein has the potential to generate
surgically implantable prechondrocyte-laden scaffolds with the
potential advantage of obviating the need for separate ex-vivo
culturing of cell-seeded scaffolds or cells. However, it is not clear
how results obtained in this study with 6-month-old rabbits will
apply to an aged human population for cartilage repair. Future
experiments in older rabbits or other species may be helpful in this
regard, but no animal model can be directly translated to humans.
Nevertheless, evidence in humans demonstrates that although the
number of multi-potent mesenchymal cells in the cambium of
periosteum is greatly reducedwith age, they still exist andmaintain
their multi-potential and proliferative capacity even in elderly
humans45,46. In addition, we recently demonstrated in rabbits, that
it is possible to increase the number of cambium cells in aged
rabbits and rejuvenate the chondrogenic potential of the perios-
teum using local growth factor injection40.
The next step will be to determine if the periosteal cell-seeded
scaffolds canbe implanteddirectly into a cartilagedefect upon removal
from the periosteum for in vivo cartilage regenerationwithout the use
of an in vitro culture step. In addition, it will be important to furthercharacterize the cells that inﬁltrate the scaffold and if necessary to
customize the scaffold to speciﬁcally select the MSCs.
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